Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings

Regeneron Pharmaceuticals (NASDAQ:REGN) on Wednesday reported better-than-expected first-quarter financial results and announced a $3 billion share buyback.